C4 Therapeutics, Inc. Common Stock (CCCC) Stock
Key stats
- Market cap
- $379.51M
- Price / Earnings ratio
- -4.3x
- EPS (TTM)
- -$0.63
- Volume
- Loading
- 52-week high
- $5.17
- 52-week low
- $1.69
Source: third-party data provider, as of November 13, 2026
Compare with CCCC
Recent news

C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
CCCC

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
CCCC

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
CCCC

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
CCCC
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 42.53
- MACD 12/26/9
- -0.03
- EMA 9 of MACD
- -0.02
- MACD histogram
- -0.01
- SMA 50
- $3.17
- Price below SMA 50
- EMA 50
- $3.22
- Price below EMA 50
- SMA 200
- $3.24
- Price below SMA 200
- EMA 200
- $3.08
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
CCCC

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
CCCC

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
CCCC

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
CCCC

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
CCCC

C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
CCCC

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
CCCC

C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
CCCC

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
CCCC

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
CCCC
News tone: automated (AI) classification of the article's content, not a price prediction.
About C4 Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Andrew J. Hirsch M.B.A. | CEO, President & Director | 1971 |
| Ms. Kendra R. Adams | Principal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer | 1977 |
| Dr. Kenneth C. Anderson M.D., Ph.D. | Co-Founder, Independent Director & Member of Scientific Advisory Board | 1951 |
| Dr. Leonard M. J. Reyno M.D. | Chief Medical Officer | 1962 |
| Dr. Nathanael S. Gray Ph.D. | Co-Founder & Member of Scientific Advisory Board | — |
| Ms. Courtney Solberg | Senior Manager of Investor Relations | — |
| Ms. Kelly A. Schick | Chief People Officer | 1980 |
| Dr. Isabel Chiu Ph.D. | Senior Vice President of Strategic Alliances & Business Development | — |
| Dr. Christopher Nasveschuk | Senior Vice President of Chemistry | — |
| Mr. Roy Pollock Ph.D. | Senior Vice President of Biological Sciences | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 42.53
- MACD 12/26/9
- -0.03
- EMA 9 of MACD
- -0.02
- MACD histogram
- -0.01
- SMA 50
- $3.17
- Price below SMA 50
- EMA 50
- $3.22
- Price below EMA 50
- SMA 200
- $3.24
- Price below SMA 200
- EMA 200
- $3.08
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $6.00
- Average
- $9.00
- High
- $11.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -11.0 | -6.4 | ||||||||||
| 2022 | -26.5 | -12.4 | +6.6 | -65.8 | -22.5 | +15.5 | +20.0 | +6.3 | -13.5 | +10.7 | -16.3 | -29.9 |
| 2023 | +22.1 | -33.4 | -37.8 | -5.6 | +4.6 | -18.2 | +37.5 | -21.8 | -35.4 | -12.4 | +23.5 | +253.1 |
| 2024 | -5.2 | +90.0 | -25.7 | -22.2 | -23.5 | -4.5 | +38.1 | -5.4 | -5.2 | -4.1 | -18.9 | -16.3 |
| 2025 | -5.2 | -19.3 | -33.3 | +13.9 | -23.3 | +7.5 | +35.8 | +22.6 | -11.6 | +21.4 | +9.3 | -24.8 |
| 2026 | -1.6 | +43.6 | -17.0 | +4.8 | +49.7 | +6.6 | -19.8 | +6.0 | -14.0 | +7.3 | -10.0 |



